A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases

International Journal of Pancreatology

Volumn 25, Issue 1, 1999, Pages 23-29

  Hayakawa, Tetsuo ^a   Naruse, Satoru ^a   Kitagawa, Motoji ^a   Ishiguro, Hiroshi ^a   Kondo, Takaharu ^a   Kurimoto, Kumiko ^b   Fukushima, Masanori ^b   Takayama, Tetsuo ^c   Horiguchi, Yuji ^d   Kuno, Nobuyoshi ^e   Noda, Aiji ^f   Furukawa, Toshiyuki ^g  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Sakashita Hospital   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e Meijo Hospital   (Japan)

^f AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^g SRL INC   (Japan)

Author keywords

Benign pancreatic disease; Diagnosis; Multivariate analysis; Pancreatic cancer; Prospective study; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PANCREAS DISEASE; PRIORITY JOURNAL;

EID: 0032957523     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:25:1:23     Document Type: Article

References (14)

1. 1 Kuno N, Kurimoto K, Fukushima M, et al. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions. Pancreas 1994; 9: 725-730.
2. 2 Pancreatic Cancer Registration Committee of Japan Pancreas Society (Chairman Saito Y). Annual report of national registration of pancreatic cancer patients in 1990 and accumulated data of 10 years between 1981 and 1990. Japan Pancreas Society, 1991.
3. 3 Furukawa T, Tsukamoto Y, Naitoh Y, et al. Differential diagnosis of pancreatic diseases with an intraductal ultrasound system. Gastrointest Endosc 1994; 40: 213-219.
4. 4 Hayakawa T, Kondo T, Shibata T, et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61: 1827-1831.
5. 5 Haglund C, Kuusela P, Jalanko H, et al. Serum CA50 as a tumor marker in pancreatic cancer: a comparison with CA19-9. Int J Cancer 1987; 39: 477-488.
6. 6 Frebourg T, Bercoff E, Manchon N, et al. The elevation of CA19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 2287-2290.
7. 7 Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-358.
8. 8 Kiriyama S, Hayakawa T, Kondo T, et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65: 1557-1561.
9. 9 Hamano H, Hayakawa T, Kondo T. Serum immunoreactive elastase in diagnosis of pancreatic diseases: a sensitive serum marker for pancreatic cancer. Dig Dis Sci 1987; 32: 50-56.
10. 10 Hayakawa T, Kondo T, Shibata T, et al. Prospective trials for early detection of pancreatic cancer by elevated serum immunoreactive elastase. Gastroenterol Jpn 1990; 25: 727-731.
11. 11 Satake K, Chung Y-S, Yokomatsu H, et al. Various tumor markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years. Pancreas 1991; 6: 234-241.
12. 12 Yamamura H, Tatsuta M, Ito M, et al. Effectiveness of discriminant analysis of serum CA19-9 and elastase 1 in diagnosis of pancreatic carcinoma. Pancreas 1989; 4: 401-405.
13. 13 Saito S, Taguchi K, Nishimura N, et al. Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma. Cancer 1993; 72: 381-388.
14. 14 Hosmer, DW, Lemeshow, S. Applied Logistic Regression. John Wiley, New York, 1989.